15353-j-veluchamy

22 | Chapter 1 Phase I Arai et al (2008) ref 49 Metastatic RCC (n=11) or Malignant Melanoma (n=1) NK-92 cell infusion Ex vivo expanded and activated allogeneic NK-92 cells. Culture duration :15-17 days with or without IL-2. *no selection Phase I (BB-IND 8847) Miller et al (2005) ref 57 Metastatic Melanoma (n=10), Metastatic RCC (n=13), Refractory HL (n=1) and AML (n=19) Conditioning with Low Cy/ mPred or Flu or high-Cy/Flu followed by NK-cell infusion; IL-2 therapy (14x, daily) Ex vivo expanded and activated PBNK-cells from haploidentical donors. Culture duration: o/n with IL-2. Abbreviations Malignancies: Central Nervous System (CNS), Myeloproliferative Disorders (MPD), Lymphoproliferative Disorder (LPD), Multiple Myeloma (MM), Myelodysplastic Syndromes (MDS), Myelodysplastic Neoplasms (MDN) Myeloproliferative Neoplasms (MPN), Acute Myeloid Leukemia (AML), Lymphoblastic Leukemia-Lymphoma (LBLL), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma (NB), Rhabdomyosarcoma (RMS), Chronic Myelogenous Leukemia (CML), Non- Hodgkin’s Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Anaplastic Large Cell Lymphoma (ALCL), Hodgkin’s Lymphoma (HL), Renal Cell Cancer (RCC), Small Cell Lung Cancer (SCLC), Chronic Lymphocytic Leukemia (CLL), Hepatocellular Carcinoma (HCC), Primitive Neuroectodermal Tumor (PNET), Adrenal Cortical Carcinoma (ACC), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL), Anaplastic Large Cell Lymphoma (ALCL), Ewing sarcoma (EWS), Desmoplastic Small Round Cell Tumor (DSRCT). Study Malignancy Clinical Trial design Culture method*